1-(3-(2-(7-氯-2-喹啉)乙烯)苯基)乙酮 | 878007-03-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-(2-(7-氯-2-喹啉)乙烯)苯基)乙酮
• 英文名称: 1-{3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}ethanone
• 英文别名: 1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)ethanone；1-{3-[(E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl}ethan-1-one；1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]ethanone
• CAS: 878007-03-5
• 化学式: C₁₉H₁₄ClNO
• 分子量: 307.779
• InChiKey: QCXCLCPLOZUDEF-WEVVVXLNSA-N

物化性质

• 沸点：
  488.9±33.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-(2-(7-氯-2-喹啉)乙烯)苯基)乙酮 在 甲烷磺酸 、 N,N-二异丙基乙胺 、 (+)-二异松蒎基氯硼烷 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 、 乙腈 为溶剂， 反应 45.5h， 生成 2-bromo-1-{3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}ethanol
  参考文献：
  名称：

  CYSTEINYL LEUKOTRIENE ANTAGONISTS

  摘要：

  本发明涉及新型半胱氨酸类白三烯（特别是LTD4）拮抗剂，主要是由一般式（I）所代表的喹啉、喹喔啉或苯[c]噻唑衍生物，或其药学上可接受的盐，其制备方法，以及在哺乳动物，特别是人类中，用这些化合物制备用于治疗与半胱氨酸类白三烯相关的疾病的药物组合物。

  公开号：

  US20140155596A1
• 作为产物：
  描述：

  (E)-3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛 在 MeMgBr 作用下， 以 四氢呋喃 为溶剂， 生成 1-(3-(2-(7-氯-2-喹啉)乙烯)苯基)乙酮
  参考文献：
  名称：

  Diarylstrylquinoline diacids and pharmaceutical compositions thereof

  摘要：

  具有以下公式的化合物：##STR1## 是白三烯拮抗剂和白细胞三烯生物合成抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。

  公开号：

  US05104882A1

文献信息

• [EN] A PROCESS FOR SYNTHESIZING DIOL (VIII)-AN INTERMEDIATE OF MONTELUKAST SODIUM<br/>[FR] PROCEDE POUR SYNTHETISER UN DIOL (VIII), INTERMEDIAIRE DU SODIUM DE MONTELUKAST
  申请人：MOREPEN LAB LTD

  公开号：WO2006021974A1

  公开（公告）日：2006-03-02

  A process comprises preparing benzaldehyde of formula I in a conventional manner, reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under 'Swern's conditions' to get a ketone of formula m, enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions effective to yield a β- ketoester of formula IV, benzylating the said β-ketoester so obtained in the preceding step to form the benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic conditions, alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired, asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII. Atemately, the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester (VI), which is converted to diol (VIII) as described herein above.

  该过程包括以传统方式制备化学式I的苯甲醛，将所述苯甲醛I与格氏试剂在水溶性醚溶剂中反应，通过加入铵盐和水使醇II沉淀，随后通过任何已知方法分离沉淀的醇，然后在“Swern条件”下直接氧化以得到化学式m的酮，使所述酮在存在弱碱（如碱金属碱）的情况下烯醇化，然后在条件下与二烷基碳酸酯反应以产生化学式IV的β-酮酯，将在前一步骤中获得的β-酮酯苄化以在温和无机碱存在下形成化学式V的苯甲酸酯，随后在酸性条件下将所述苯甲酸酯脱羧为化学式VI的酮酯和其对应酸化学式VIA的混合物，将在前一步骤中存在的酸VIA烷化以获得化学式VI的酮酯，并在必要时纯化，将化学式VI的酮酯不对称还原为手性醇化学式VII，使用(-)二异萜基氯硼烷(-DIPC1)在少于4倍体积/重量的无极性溶剂和可能在存在于所述化学式VI的酮酯相对于Lewis碱的情况下，用铈卤盐和烷基镁卤化物处理所述手性醇VII，随后使用hyflow supercel和氯化铵分离标题化合物以获得化学式VIII的中间二醇。或者，将所述醇与甲基-2-碘苯酸甲酯在Lewis碱、乙腈和乙酸钯存在下进行Heck偶联反应，得到酮酯(VI)，然后将其转化为所述化学式VIII的二醇，如上所述。
• Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
  申请人：Merck Frosst Canada, Inc.

  公开号：US05270324A1

  公开（公告）日：1993-12-14

  Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

  具有以下化学式的化合物 I: ##STR1## 是白三烯拮抗剂，也是白三烯生物合成的抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎症和细胞保护剂。它们还可用于治疗心绞痛、脑痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。
• Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
  申请人：Merck Frosst Canada, Inc.

  公开号：US05565473A1

  公开（公告）日：1996-10-15

  Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

  具有以下化学式I的化合物是白三烯拮抗剂和白三烯生物合成抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。
• Cysteinyl leukotriene antagonists
  申请人：Rathod Rajendrasinh

  公开号：US09102665B2

  公开（公告）日：2015-08-11

  The present invention relates to novel cysteinyl leukotriene (specifically LTD4) antagonists, mainly to quinolin, quinoxaline or benz[c]thiazole derivatives represented by the general formula (I), or the pharmaceutically acceptable salt thereof, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to cysteinyl leukotriene, in mammals, more specially in humans.

  本发明涉及一种新型半胱氨酸白三烯（特别是LTD4）拮抗剂，主要是由通式（I）所代表的喹啉，喹噁啉或苯[c]噻唑衍生物或其药学上可接受的盐，其制备过程，以及将该化合物用于制备药物组合物，以治疗与半胱氨酸白三烯相关的疾病，在哺乳动物中，更特别是在人类中的治疗。
• Diarylstyrylquinoline diacids
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0399818A1

  公开（公告）日：1990-11-28

  Compounds having the formula: are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

  具有以下式子的化合物 是白三烯拮抗剂和白三烯生物合成抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。